Tagged with CNS

Sweden BioArctic is a Swedish biopharma company with the vision to become a world-leader in the research and development of disease-modifying treatments for patients with neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and pioneering treatment methods for complete spinal cord injuries. Gunilla Osswald, CEO, explains how BioArctic is uniquely…

Sweden Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the first disease-modifying treatment for Alzheimer’s Disease and the next global blockbuster.   The results from the Phase IIb study strengthen BioArctic’s belief that BAN2401’s unique binding profile is…

Alzheimer's Alzheimer’s drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, “Except for one good piece of news in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure…

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it.   45 percent of the patient population in neurology remains unserved – they either have no…

Turkey From collaborating with authorities to tackling awareness surrounding mental illnesses, Altan Gorseval, country manager of Lundbeck Turkey, paints an accurate picture of the company’s dedication to improving mental health and patient outcomes in the country. What have been your strategic priorities for Lundbeck Turkey over the past two years? Our…

Brazil Jun Eguti, general manager of Grünenthal Brazil, highlights the global transformation Grünenthal has undergone in the past two years, the huge potential the Brazilian affiliate has to become one of the largest in LatAm and the exciting product pipeline the affiliate has in Pain Management, Women’s Health, CNS and Gout…

Tunisia Habib Toumi, CEO of the Tunisian National Social Security Fund (CNSS), discusses implementing universal healthcare coverage, restoring the financial equilibrium of the fund, and managing the continuous improvement of services provided in the CNSS policlinics. Can you describe the operational characteristics of the Tunisian National Social Security Fund (CNSS)? “Concerning…

Taiwan Ming-Kuei Jang, founder and CEO of Aprinoia, a very promising Taiwan-based company focused on the development of groundbreaking imaging tracers and therapeutics targeting tau-related neurodegenerative diseases, provides insights into the company’s rapid development over the past two years, its R&D strategy, and its eagerness to partner with both academia and…

Taiwan With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral sciences at the University of California, Los Angeles (UCLA), is an internationally reputed scientist in neurosciences and brain disorders, whose…

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…

R&D Lundbeck Turkey’s managing director discusses CNS and mental illness in Turkey, and their recent development of manufacturing operations in Turkey for their new product. Given this specialization in and deep knowledge of CNS, how would you assess the Turkish medical systems’ ability to handle mental illness? First of all, when…